Bull of the Day: AXT (AXTI)

AXT reported record Q2 2026 revenue of $47.6 million, up 164%-165% year over year, with GAAP gross margin reaching 44.9%, InP revenue of $30.7 million, and approximately $11.1 million in GAAP net income. The company has more than $100 million in backlog and plans to expand quarterly InP capacity from roughly $35 million by end-2026 to $65-$70 million in 2027/early 2028, supporting analyst expectations for revenue above $215 million this year and about $450 million next year. The investment case centers on InP substrates for AI optical interconnects and co-packaged optics, although China-based manufacturing, export controls, competing photonic technologies, and potential capacity oversupply remain material risks.

Analysis

The investable issue is not optical-connectivity demand but whether AXTI can monetize scarcity before its own expansion removes it. Near-term capacity headroom appears limited relative to the current InP run-rate, so the next 1-3 quarters should feature favorable mix and utilization; the 2027 expansion, however, creates a step-function execution risk if customer qualification or CPO adoption slips. Backlog alone is insufficient proof of multi-year earnings durability unless disclosed as binding, non-cancellable orders with pricing protection.

AXTI's China-based manufacturing and raw-material ownership create a two-sided asymmetry: vertical integration can protect indium availability and gross margin during shortages, but a China-related licensing, export-control, or local operating disruption would impair the entire production chain rather than merely raise input costs. Its U.S. corporate domicile should not command a strategic-supplier premium without evidence that critical production can be qualified outside China. LITE and COHR are likely better positioned to pass through component scarcity to systems customers, while AXTI has the greater incremental margin sensitivity but also the greater single-point geopolitical exposure.

Consensus is likely extrapolating a peak-utilization quarter into a smooth multi-year curve. The key falsifier is not revenue growth alone: InP revenue below roughly $25M for two consecutive quarters, gross margin below 40%, or capacity additions without a corresponding increase in booked supply commitments would imply that recent profitability is cyclical rather than structural. Conversely, qualification of larger-diameter wafers and disclosed take-or-pay commitments could justify a durable multiple premium, but those are 6-18 month catalysts rather than reasons to chase a sharp near-term rebound.

Key Decisions for Investors

• Initiate only a half-size AXTI long on a pullback below $60 or after the next report confirms InP revenue above $30M and gross margin above 42%; target a 6-12 month re-rating toward prior highs, with a hard thesis review if shares close below $50 following results.
• Structure the exposure as long AXTI / short SOXX or SMH at roughly 1.5-2.0x hedge beta for the next 3 months. This isolates substrate-specific execution from a broad AI-capex de-rating; exit the hedge if disclosed contracted demand converts the story from spot scarcity to visible 2027 revenue.
• Do not use LITE or COHR as outright shorts against AXTI: both can benefit from the same optical upgrade cycle and have more diversified product portfolios. Instead, monitor their optical-component bookings and inventory commentary as a leading indicator for AXTI demand; weakening orders at either would be an AXTI risk alert.
• Ahead of the next earnings release, price AXTI options only if implied volatility is below the expected post-result move; otherwise retain cash for a post-report entry. The missing diligence item is the duration, cancellation terms, and customer concentration of supply agreements—without it, avoid increasing beyond a starter position.